A 45-year-old woman presents with long-standing exertional dyspnea, wheezing, and intermittent dry cough, which has been ongoing for over the past 10 years.

After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its ...

The American College of Chest Physicians recently released a new clinical guideline on biologic management in severe asthma.

(StatePoint) If you’re one of the 35 million people living with a chronic lung disease in the United States, the form of treatment you receive can impact your health outcomes and quality of life. That ...

Background: Long-acting beta-agonist (LABA) plus long-acting muscarinic antagonist (LAMA) is superior to monotherapy or corticosteroid/LABA in terms of improving lung function, alleviating symptoms ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about oligonucleotides. The drugmaker is paying $85 million upfront to Empirico ...

Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a ...

AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (UTHR) announced today that it will host a webcast to review data from the successful TETON-2 ...

Posters support Ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Verona ...

The last time I spoke about United Therapeutics (UTHR) it was with respect to a Seeking Alpha article entitled "United Therapeutics: Ability To Expand Tyvaso To Large IPF Market". With respect to this ...